Mainz Capex To Revenue from 2010 to 2024

MYNZ Stock  USD 0.88  0.01  1.15%   
Mainz Biomed Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
(2.12)
Current Value
(2.01)
Quarterly Volatility
0.75506909
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mainz Biomed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mainz main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 909.7 K or Interest Expense of 419.9 K, as well as many exotic indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0 or PTB Ratio of 6.09. Mainz financial statements analysis is a perfect complement when working with Mainz Biomed Valuation or Volatility modules.
  
This module can also supplement various Mainz Biomed Technical models . Check out the analysis of Mainz Biomed Correlation against competitors.

Latest Mainz Biomed's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Mainz Biomed BV over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Mainz Biomed's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mainz Biomed's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Mainz Capex To Revenue Regression Statistics

Arithmetic Mean(0.37)
Coefficient Of Variation(201.60)
Mean Deviation0.57
Median(0.02)
Standard Deviation0.76
Sample Variance0.57
Range2.1009
R-Value(0.69)
Mean Square Error0.32
R-Squared0.48
Significance0
Slope(0.12)
Total Sum of Squares7.98

Mainz Capex To Revenue History

2024 -2.01
2023 -2.12
2022 -1.24
2021 -0.0289

About Mainz Biomed Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Mainz Biomed income statement, its balance sheet, and the statement of cash flows. Mainz Biomed investors use historical funamental indicators, such as Mainz Biomed's Capex To Revenue, to determine how well the company is positioned to perform in the future. Although Mainz Biomed investors may use each financial statement separately, they are all related. The changes in Mainz Biomed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mainz Biomed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Mainz Biomed Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Mainz Biomed. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue(2.12)(2.01)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mainz Biomed BV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mainz Biomed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mainz Biomed Bv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mainz Biomed Bv Stock:
Check out the analysis of Mainz Biomed Correlation against competitors.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Mainz Stock analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Mainz Biomed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mainz Biomed. If investors know Mainz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mainz Biomed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
0.055
Quarterly Revenue Growth
0.111
Return On Assets
(0.93)
Return On Equity
(3.03)
The market value of Mainz Biomed BV is measured differently than its book value, which is the value of Mainz that is recorded on the company's balance sheet. Investors also form their own opinion of Mainz Biomed's value that differs from its market value or its book value, called intrinsic value, which is Mainz Biomed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mainz Biomed's market value can be influenced by many factors that don't directly affect Mainz Biomed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mainz Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mainz Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mainz Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.